PLAU (plasminogen activator urokinase) mRNA has also been shown to be significantly elevated in HNSCC tumour samples over normal specimens, with evidence for PLAU as an independent indicator for HNSCC prognosis [39] associated with poorer clinical outcomes [40]. The gene discussed is PLAU; the disease is neoplasm.